Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 03
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Pharming Group
PHAR
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$12.73
0.50
4.09%
Ult. Agg.: Nov 2, 7:07 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Confronta
Rapporto azionario
Utili:
I risultati di Q3 2026 sono stati pubblicati in data mar ott 27th, prima dell'apertura del mercato
Conference call:
La conference call più recente è iniziata alle 8:30 AM, 6 giorni fa
Clicca per vedere il webcast
Pharming Financials
Pharming (PHAR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est
Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $380.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.333 million estimate.
Benzinga Newsdesk
PRO
Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.02 by 1400 percent. This is a 200 percent increase over earnings of $0.10 per share from the same
Benzinga Newsdesk
PRO
Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est
Pharming (NASDAQ:PHAR) narrows FY2026 sales outlook from $375.000 million-$395.000 million to $380.000 million-$390.000 million vs $389.333 million estimate.
Benzinga Newsdesk
PRO
Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter
Benzinga Newsdesk
PRO
Pharming Lowers FY2026 Sales Guidance from $405.000M-$425.000M to $375.000M-$395.000M vs $419.100M Est
Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.000 million-$395.000 million vs $419.100 million estimate.
Benzinga Newsdesk
PRO
Pharming Q2 EPS $0.02, Inline, Sales $90.200M Miss $100.625M Estimate
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period last year. The
Benzinga Newsdesk
